- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02355730
Blood Donation From Warfarin Users for the Development of POC INR Monitor
Blood Donation for the Development and Optimisation of the Second Generation Microvisk International Normalized Ratio (INR) Testing System for the Measurement of Prothrombin Time (PT)/INR in Patients on Warfarin Therapy.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The number of patients receiving anticoagulation therapy with warfarin and other vitamin K antagonists has been rising in recent years. Increasing life expectancy is increasing the proportion of the population having conditions such as Atrial Fibrillation and venous thrombosis, where primary and secondary prevention of thromboembolic complications are best achieved with anticoagulation.
Unpredictable pharmacokinetics, widespread interactions with drugs and food and the narrow therapeutic window make closely monitoring Vitamin K antagonists a necessity. Portable point of care (POC) coagulometers which measure PT from capillary whole blood and provide an INR reading within a few minutes are already widely available throughout North American and Europe. They give comparable results when compared to laboratory based systems are popular with patients and significantly shorten the duration of clinics. In addition, the United Kingdom Department of Health has been encouraging the use of anticoagulation services in Primary Care Trusts the aim being to provide INR monitoring in community clinics and General Practice surgeries relieving pressure on hospital services and reducing inconvenience for patients.
Although coagulometers are now commercially available the Microvisk INR Testing System has been designed to have advantages, particularly in terms of test robustness, user comfort, ease of use and reduction of user error. The present trial has been designed to develop the second generation Microvisk INR Test System; blood samples will also be used to optimise manufacturing processes and verify the quality of Test Strip Lots.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Joseph Booth
- Telefonnummer: +44 845 956 9900
- E-post: joebooth@microvisk.com
Studiesteder
-
-
Merseyside
-
Liverpool, Merseyside, Storbritannia, L7 8XP
- Rekruttering
- Royal Liverpool & Broadgreen University Hospital NHS Trust
-
Ta kontakt med:
- Colin Downey
- Telefonnummer: +44 151 706 4322
- E-post: Colin.Downey@rlbuht.nhs.uk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subject is male or female, greater than 18 years of age
- Subject is receiving warfarin (or warfarin-like) therapy as part of their clinical care
- Subject is informed and has been given ample time and opportunity to think about his/her participation and has given his/her written informed consent
Exclusion Criteria:
- Subjects aged <18 years of age
- Subjects who are unable to give written consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Warfarin Patients
Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
|
Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The Primary Outcome will be measured in terms of differences in International Normalised Ratio when the Generation 2 system is tested against the Generation 1 system using the blood samples from the same donors.
Tidsramme: 2 years
|
The Primary Outcome will be measured in terms of differences in International Normalised Ratio when the Generation 2 system is tested against the Generation 1 system using the blood samples from the same donors.
Those differences will be reported in terms of accuracy, precision and sensitivity to interferents.
|
2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The Secondary Outcome will be measured in terms of differences in International Normalised Ratio when the Generation 2 system is tested against the International Standard Method using the blood samples from the same donors.
Tidsramme: 2 years
|
A master batch of test strips will be calibrated against an International Reference Preparation (rTF/09) thromboplastin.
The accuracy of the master batch will be verified using patient samples.
|
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Cheng-Hock Toh, Professor, Royal Liverpool and Broadgreen University Hospital Trust
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RDE03
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Atrieflimmer
-
Pusan National University HospitalHar ikke rekruttert ennåHjerteimplanterbar elektronisk enhet | Atrial High Rate EpisodeKorea, Republikken
-
W.L.Gore & AssociatesFullført
-
The Second Affiliated Hospital of Chongqing Medical...UkjentAtrieflimmer | Hjerteombygging, atrial | Sacubitril/Valsartan
-
Helios Klinikum PforzheimRekrutteringHøyre hjertesvikt | Trikuspidal regurgitasjon | Hjerteombygging, Ventrikulær | Hjerteombygging, atrialTyskland
-
Henry Ford Health SystemTilbaketrukket
-
Nobles Medical Technologies II IncPåmelding etter invitasjonForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater, Italia
-
HeartStitch.ComUkjentForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater
-
China National Center for Cardiovascular DiseasesRekrutteringHjertesykdommer | Atrial septal dilatasjonKina
-
Assiut UniversityUkjent
-
Amsterdam UMC, location VUmcRekruttering